Prostate Cancer: Beyond First Line Hormones
CME Monograph - October 2006
This educational monograph was developed for urologists and oncologists who assess and treat patients with prostate cancer.
The program faculty were Philip W. Kantoff, MD, Chief, Division of Solid Tumor Oncology, Dana-Farber Cancer Institute; William K. Oh, MD, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute; Robert Dreicer, MD, FACP, Chairman, Department of Solid Tumor Oncology, The Cleveland Clinic and Maha H. Hussain, MD, FACP, Professor of Medicine and Urology, Comprehensive Cancer Center, University of Michigan.
Educational Objectives
1) Describe measures for evaluating patients with a rising PSA on first-line hormonal therapy to assess whether they may have metastatic disease and/or require second-line therapy; 2) assess current and near-term therapeutic options for treating patients with hormone refractory disease and list four national clinical trials currently enrolling patients with hormone refractory disease; and 3) list at least one internet site where physicians and patients can find current information on clinical trials.
Educational Grant Support
The program was supported by educational grants provided by Abbott Laboratories and sanofi-aventis, U.S.
Sponsorship
CME sponsorship and program management were provided by InforMEDical.
The CME activity was effective October 2006 through September 2008.
